FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386982899> ?p ?o ?g. }

• W4386982899 abstract "Nonalcoholic fatty liver disease (NAFLD) is a complex metabolic disorder that increases the risk for cardiovascular disease in patients with type 2 diabetes mellitus (T2DM). Global longitudinal strain (GLS) is an indicator of left ventricular (LV) mechanics and can detect subclinical myocardial dysfunction. We compared the effects of pioglitazone and empagliflozin on GLS in patients with T2DM and NAFLD without established atherosclerotic cardiovascular disease.This study was a 24-week randomized, single-blind, and parallel-group (1: 1 ratio) clinical trial. Seventy-three participants with T2DM (being treated with metformin) and NAFLD but without established atherosclerotic cardiovascular disease (ASCVD) were randomized to empagliflozin or pioglitazone. Liver steatosis and fibrosis were measured using transient elastography, and GLS was measured by echocardiography. The primary endpoint was the change in GLS from baseline to week 24. Secondary end points include changes in controlled attenuation parameter (CAP) and Liver stiffness measure (LSM).In this study, GLS improved by 1.56 ± 2.34% (P < 0.01) in the pioglitazone group and 1.06 ± 1.83% (P < 0.01) in the empagliflozin group without a significant difference between the two groups (P = 0.31). At baseline, GLS was inversely associated with the severity of liver fibrosis: r = - 0.311, P = 0.007. LSM in the pioglitazone and empagliflozin group [(-0.73 ± 1.59) and (-1.11 ± 1.33)] kpa (P < 0.01) decreased significantly. It was without substantial difference between the two groups (P = 0.26). Empagliflozin and pioglitazone both improved controlled attenuation parameter. The improvement was more critical in the empagliflozin group: -48.22 + 35.02 dB/m vs. -25.67 + 41.50 dB/m, P = 0.01.Subclinical cardiac dysfunction is highly important in patients with T2DM and with NAFLD. Empagliflozin and Pioglitazone improve LV mechanics and fibrosis in patients without established ASCVD. This has a prognostic importance on cardiovascular outcomes in high-risk patients with T2DM. Moreover, empagliflozin ameliorates liver steatosis more effectively them pioglitazone. This study can serve as a start point hypothesis for the future. Further studies are needed to explore the concept in larger populations.This trial was registered in the Iranian Registry of Clinical Trials (IRCT): A Comparison between the Effect of Empagliflozin and Pioglitazone on Echocardiographic Indices in Patients with Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease IRCT20190122042450N5, 29 November 2020. https://www.irct.ir/search/result?query=IRCT20190122042450N5 ." @default.
• W4386982899 created "2023-09-24" @default.
• W4386982899 creator A5018868905 @default.
• W4386982899 creator A5021150239 @default.
• W4386982899 creator A5025802310 @default.
• W4386982899 creator A5047030147 @default.
• W4386982899 creator A5048819619 @default.
• W4386982899 creator A5053029090 @default.
• W4386982899 creator A5063484171 @default.
• W4386982899 creator A5071251589 @default.
• W4386982899 date "2023-09-23" @default.
• W4386982899 modified "2023-10-18" @default.
• W4386982899 title "Effect of Empagliflozin and Pioglitazone on left ventricular function in patients with type two diabetes and nonalcoholic fatty liver disease without established cardiovascular disease: a randomized single-blind clinical trial" @default.
• W4386982899 cites W1539916041 @default.
• W4386982899 cites W1604487092 @default.
• W4386982899 cites W1870638042 @default.
• W4386982899 cites W1967999753 @default.
• W4386982899 cites W1968813434 @default.
• W4386982899 cites W1971207050 @default.
• W4386982899 cites W1995461319 @default.
• W4386982899 cites W2001984572 @default.
• W4386982899 cites W2020417496 @default.
• W4386982899 cites W2026049223 @default.
• W4386982899 cites W2027466456 @default.
• W4386982899 cites W2058320068 @default.
• W4386982899 cites W2062812115 @default.
• W4386982899 cites W2067184340 @default.
• W4386982899 cites W2077666699 @default.
• W4386982899 cites W2095755100 @default.
• W4386982899 cites W2096431106 @default.
• W4386982899 cites W2098766590 @default.
• W4386982899 cites W2105400632 @default.
• W4386982899 cites W2112560527 @default.
• W4386982899 cites W2119200010 @default.
• W4386982899 cites W2124624517 @default.
• W4386982899 cites W2237544788 @default.
• W4386982899 cites W2283015603 @default.
• W4386982899 cites W2398640998 @default.
• W4386982899 cites W2625462710 @default.
• W4386982899 cites W2788464339 @default.
• W4386982899 cites W2790015075 @default.
• W4386982899 cites W2908524400 @default.
• W4386982899 cites W2911172690 @default.
• W4386982899 cites W2936593438 @default.
• W4386982899 cites W2938851021 @default.
• W4386982899 cites W2968982492 @default.
• W4386982899 cites W3005290255 @default.
• W4386982899 cites W3044676930 @default.
• W4386982899 cites W3064545748 @default.
• W4386982899 cites W3088344065 @default.
• W4386982899 cites W3129584656 @default.
• W4386982899 cites W3130225195 @default.
• W4386982899 cites W4213447109 @default.
• W4386982899 cites W4225403185 @default.
• W4386982899 cites W4225594739 @default.
• W4386982899 cites W4249896096 @default.
• W4386982899 cites W4250651361 @default.
• W4386982899 doi "https://doi.org/10.1186/s12876-023-02948-4" @default.
• W4386982899 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37742004" @default.
• W4386982899 hasPublicationYear "2023" @default.
• W4386982899 type Work @default.
• W4386982899 citedByCount "0" @default.
• W4386982899 crossrefType "journal-article" @default.
• W4386982899 hasAuthorship W4386982899A5018868905 @default.
• W4386982899 hasAuthorship W4386982899A5021150239 @default.
• W4386982899 hasAuthorship W4386982899A5025802310 @default.
• W4386982899 hasAuthorship W4386982899A5047030147 @default.
• W4386982899 hasAuthorship W4386982899A5048819619 @default.
• W4386982899 hasAuthorship W4386982899A5053029090 @default.
• W4386982899 hasAuthorship W4386982899A5063484171 @default.
• W4386982899 hasAuthorship W4386982899A5071251589 @default.
• W4386982899 hasBestOaLocation W43869828991 @default.
• W4386982899 hasConcept C126322002 @default.
• W4386982899 hasConcept C134018914 @default.
• W4386982899 hasConcept C164705383 @default.
• W4386982899 hasConcept C168563851 @default.
• W4386982899 hasConcept C2775887513 @default.
• W4386982899 hasConcept C2776175330 @default.
• W4386982899 hasConcept C2776954865 @default.
• W4386982899 hasConcept C2777180221 @default.
• W4386982899 hasConcept C2778384471 @default.
• W4386982899 hasConcept C2778772119 @default.
• W4386982899 hasConcept C2779134260 @default.
• W4386982899 hasConcept C2779306644 @default.
• W4386982899 hasConcept C2780323712 @default.
• W4386982899 hasConcept C2910068830 @default.
• W4386982899 hasConcept C555293320 @default.
• W4386982899 hasConcept C71924100 @default.
• W4386982899 hasConcept C90924648 @default.
• W4386982899 hasConceptScore W4386982899C126322002 @default.
• W4386982899 hasConceptScore W4386982899C134018914 @default.
• W4386982899 hasConceptScore W4386982899C164705383 @default.
• W4386982899 hasConceptScore W4386982899C168563851 @default.
• W4386982899 hasConceptScore W4386982899C2775887513 @default.
• W4386982899 hasConceptScore W4386982899C2776175330 @default.
• W4386982899 hasConceptScore W4386982899C2776954865 @default.
• W4386982899 hasConceptScore W4386982899C2777180221 @default.
• W4386982899 hasConceptScore W4386982899C2778384471 @default.
• W4386982899 hasConceptScore W4386982899C2778772119 @default.
• W4386982899 hasConceptScore W4386982899C2779134260 @default.

• next